Very substantial disposal in relation to the license and assignment agreement
Filed with HKEX · Stock code 2126 · · 32 pages · English
Summary by 6ix AI
JW (Cayman) Therapeutics Co. Ltd. has announced a very substantial disposal related to a License and Assignment Agreement with Eureka Hong Kong, involving the assignment of certain assets and licensing rights. The transaction is significant as it exceeds the threshold defined by the Listing Rules, requiring shareholder approval and further disclosures. An extraordinary general meeting will be convened for shareholders to approve the agreement and its terms. The effectiveness of the agreement is contingent upon obtaining necessary approvals and the absence of any prohibitive legal orders.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
JW (Cayman) Therapeutics Co. Ltd. on 6ix
Earlier from JW (Cayman) Therapeutics
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- 2026 Interim report
- JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential
- JW Therapeutics Announces Approval of Relmacabtagene Autoleucel Injection (Carteyva®) for Marketing in Macao
Follow JW (Cayman) Therapeutics into a list and get an email when it puts out news.
Follow JW (Cayman) Therapeutics